Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Podcast: Ethics of Global Clinical Trials

Dr. Russell Medford

Holland & Knight’s Michael Werner talks to Dr. Russell Medford, President and CEO of Salutria Pharmaceuticals, a privately-held biotech company based in Alpharetta Georgia. Dr. Medford is also co-chair of BIO’s Board Standing Committee on Bioethics. Dr. Medford will be providing testimony on Wednesday November 16 to the Presidential Commission for the Study of Bioethical Issues on Principles Regarding Ethical Performance of International Clinical Trials.

Health  |  Leave a comment  |  Email This Post

Foundation Fighting Blindness Invests in Gene Therapy Research Projects

567497167_0ee54c371c_z

Recently, the Foundation Fighting Blindness announced an $8.25 million investment in six new gene therapy research projects targeted to have treatments ready for clinical trials within three years. The projects include the following: The Institut de la Vision in Paris and the Friedrich Miescher Institute in Basel, Switzerland, are developing a gene therapy that may revive degenerating cones and potentially enable them to regain their ability to respond to light and provide vision. The treatment Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Beyond the ABCs of ADCs

Antibody

The recent FDA approval of Seattle Genetics’ antibody, Adcetris, has cast the spotlight on Antibody Drug Conjugates (ADC), leaving experts to contemplate whether this is the peak for ADCs. If history has its say though, the spotlight won’t be flickering anytime soon. Experts in this specialized antibody field discussed the latest developments and lessons of bringing ADCs through the clinic at this week’s 10th Annual BIO Investor Forum. Antibody drug conjugates hold enormous potential for treating Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Multiple Assets Diversify the Deal

Partnering Meeting

With a recent surge in pharma companies collaborating earlier on with small biotech companies, discovery stage partnering deals are becoming increasingly popular.  Striking a discovery stage deal can be extremely beneficial for both parties in today’s environment – pharma gets to fill its ever elusive R&D pipeline as patent expirations loom, and the small biotech struggling to raise money to stay alive gets the capital infusion necessary to stay in play. Panelists in the “Broad Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Medical Innovation at Risk

Scientists

The National Venture Capital Association’s MedIC Coalition recently released a report showing U.S. venture capitalists are decreasing their investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas and shifting investments towards Europe and Asia. The report, Vital Signs: The Threat to Investment in U.S. Medical Innovation and the Imperative of FDA Reform, strongly indicates that America’s medical innovation economy is in grave danger of losing its primary source of funding, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,